Erratum: Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours (British journal of cancer (2018) 118 2 (153-161))

Jeffrey R. Infante, Ronald L. Korn, Lee S. Rosen, Patricia LoRusso, Samuel S. Dychter, Joy Zhu, Daniel C. Maneval, Ping Jiang, H. Michael Shepard, Gregory Frost, Daniel D. Von Hoff, Mitesh J. Borad, Ramesh K. Ramanathan

Research output: Contribution to journalComment/debate

Abstract

This corrects the article DOI: 10.1038/bjc.2017.327.

Original languageEnglish (US)
Pages (from-to)e3
JournalBritish journal of cancer
Volume118
Issue number2
DOIs
StatePublished - Jan 1 2018

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Erratum: Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours (British journal of cancer (2018) 118 2 (153-161))'. Together they form a unique fingerprint.

  • Cite this

    Infante, J. R., Korn, R. L., Rosen, L. S., LoRusso, P., Dychter, S. S., Zhu, J., Maneval, D. C., Jiang, P., Shepard, H. M., Frost, G., Von Hoff, D. D., Borad, M. J., & Ramanathan, R. K. (2018). Erratum: Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours (British journal of cancer (2018) 118 2 (153-161)). British journal of cancer, 118(2), e3. https://doi.org/10.1038/bjc.2017.438